Welcome to Terry’s Corner , where foundational pharmacology is demystified by someone who’s spent over In his newest lesson, “The Uniqueness of Pharmacology in Drug Discovery,” Terry Kenakin explains why pharmacology isn’t a clean-cut science—it’s a dynamic dialogue between molecule and system. You’ll uncover: Why pharmacology is the glue between chemistry and biology How to interpret drug behavior the story it’s telling. 👉 Start your journey with Terry’s foundational series Unlock "Unique Role of Pharmacology

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

Did you know that each month we collect the most recent #GPCR publications and the newest Biotech/Pharma

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

This Week’s Highlights: G protein-coupled receptor (GPCR) pharmacogenomics Miles D Thompson , David Jonasson, CFO & CBO at Absci Octant: A Next Generation Approach to Genetic Disease Antiverse, Nxera Pharma to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox GPCR Jobs NEW GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Research Associate - Professor Graeme Milligan Postdoc in Molecular Pharmacology - The Hauser Group

We’ve made some updates to the Principles of Pharmacology I & II courses, and we can’t wait for you Here’s the refreshed schedule: Principles of Pharmacology I October 3, 10, 17, 24 Principles of Pharmacology Don’t miss out on insightful resources like '   Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR Pharmacology .' Don’t miss your chance to dive into the Principles of Pharmacology I & II BUNDLE .

Pharma, biotech, academia, core facilities, and students are all welcome.

As Chief Matchmaker, I recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals.  Beth is also the hiring manager for their open Principal Scientist, In Vitro Pharmacology role posted Top candidates will have a solid foundation in GPCR pharmacology as well as some experience in drug discovery

Richard is the architect behind nearly all of Exscientia's partnerships and collaborations across pharma

This week's highlights: Driving Pharma Innovation in Oncology: Domain Therapeutics' Success Proven by The Neuromedin U system: pharmacological implications for the treatment of obesity and binge eating behavior 2023 Financial Results Scientists Discover a New Way To Develop Drugs Without Side Effects Driving Pharma

I We are diving into the second class of our Principles of Pharmacology I course with enthusiasm and Seize this opportunity to enhance your expertise and proficiency in pharmacology! Modules: October 31st : The Eyes to See- The Importance of Pharmacologic Assays. s dive into the   Classified GPCR News from September 30th to October 6th, 2024 Industry News Nxera Pharma experienced commercial R&D executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma

treatment selection in patients with advanced haematological cancers, international partnerships with pharma

and Daniel Isom  for their research on Advances in yeast synthetic biology for human GPCR biology and pharmacology Materials Access to the private group Certificate of participation Learn the essentials: Measuring the pharmacologic genetic disease Advances in yeast synthetic biology for human G protein-coupled receptor biology and pharmacology DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma 7, 2024 | 16th Annual PEGS Europe   July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology

efficacy, selectivity, and safety Profile biased signaling, allosteric modulation, and species-specific pharmacology "Eurofins Discovery brings real breadth and depth in GPCR pharmacology, and I am glad to feature them researchers from target validation through candidate advancement, spanning screening, functional and binding pharmacology

It is a timely look at how receptor pharmacology can sharpen one of the most talked-about therapeutic Kenakin's teaching, Terry's Corner is our room where he breaks down receptor pharmacology, functional

Fingerprint To obtain a pharmacological fingerprint (or profile) for GPCR therapeutics, it is best to Expanding the Druggable Target Space Through Bias Beyond refining the pharmacology of established targets Journal of Pharmacology and Experimental Therapeutics, 314(3), 1195–1201. https://doi.org/10.1124/jpet Journal of Pharmacology and Experimental Therapeutics, 344 (3), 708–717. https://doi.org/10.1124/jpet Journal of Pharmacology and Experimental Therapeutics, 335 (3), 572–579. https://doi.org/10.1124/jpet

is a precision mismatch Hybrid ligand design: how two pharmacophores are encoded into one scaffold, It is a pharmacological signature of two processes with different temporal profiles. Dr. It is pharmacologically complex in a way that steady-state measurement assigns no value to. That reframing is what makes the underlying pharmacological complexity visible. Terry's Corner is the room where pharmacologists work through frameworks like these alongside Dr.

A Specific Difficulty, Not a General Verdict A pharmacologist designing an orthosteric small-molecule Together, they form what receptor pharmacologists describe as affinity traps: distributed networks of These are pharmacological frameworks, and small-molecule intuition does not transfer cleanly to all of Terry's Corner is the room where pharmacologists work through frameworks like these alongside Dr. This is where receptor pharmacologists who take interpretation seriously sharpen their thinking together

The gap between pharmacological screening and clinical translation has a structural explanation. HEK293 systems have driven pharmacological screening for decades — and for good reason. In these systems, receptor pharmacology can be examined alongside disease-relevant phenotypic responses into disease-relevant environments, and what the implications are for translational pharmacology programs The binding mode of a new molecule isn't a footnote in pharmacology.

University iPSC-Derived Systems for GPCR Signaling and Translation HEK293 systems are powerful tools for pharmacological patient-derived induced pluripotent stem cells (iPSCs), organoid systems, and biosensor-based assays extend GPCR pharmacology Whether a molecule binds at the orthosteric or allosteric site determines its pharmacological behavior and κ-opioid receptors, acting differently at each — a concrete illustration of how receptor-specific pharmacology

Systems for GPCR Signaling and Translation Heterologous systems such as HEK293 cells enable scalable pharmacological examine how iPSC-derived cardiomyocytes , organoid systems , and biosensor-based assays extend GPCR pharmacology Reserve your spot ➤ GPCR Pharmacology: Open Problems and Discussion Binding assays and functional assays GPCR brings together scientists working across GPCR biology, pharmacology, and drug discovery to examine

The Cell Surface Is Only Part of the Story For decades, GPCR pharmacology centered on events at the cell The model needs to account for the possibility that both arms of the pharmacological response — activation The same receptor, the same second messenger, but two fundamentally different pharmacological profiles Pharmacological tools such as Dynasore — a GTPase inhibitor of dynamin 1 and 2 — block internalization It is part of a structured environment where pharmacologists sharpen their thinking on exactly these

System Context Determines Pharmacology Allosteric behavior is not intrinsic to the ligand alone; it depends What Members Say “I think Terry’s Corner is a fantastic resource that can benefit any pharmacologist No matter what I’ve read or learned during my 30+ years as a practicing receptor pharmacologist, I always The discussions extend beyond curve fitting into the structure of pharmacological reasoning itself. For pharmacologists refining assay interpretation, for teams navigating conflicting data, and for leaders

Complex Than It Looks G protein-coupled receptors (GPCRs) have long occupied a privileged position in pharmacology Allosteric Modulation and the Microcircuit Model of GPCR Pharmacology Understanding GPCRs as allosteric The reverse pharmacology approach — starting from a synthetic ligand with measurable receptor activity It also requires alignment between in vitro   GPCR assay  data and pharmacokinetic measurements. Biased signaling  opens up opportunities beyond just binary on/off pharmacology.

discovery teams from advancing compounds based on artifacts of expression systems rather than intrinsic pharmacology If the assay threshold is too high, real pharmacology becomes invisible. Whole-Cell Responses: A Historical Complication Historically, pharmacology relied on whole-cell or tissue Why Terry’s Corner Terry’s Pharmacology Corner delivers weekly lectures from Dr. It is designed for: Pharmacologists sharpening foundational tools Discovery teams solving assay bottlenecks

GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry The final pharmacophore is derived from a set of at least 3-5 different chemical scaffolds. The pharmacophore is then functionalized in the best position for introducing a linker. This provides valuable information regarding the potential fitting of our three pharmacophores through Biomedicine & Pharmacotherapy 2022 , 153 , 113408. https://doi.org/10.1016/j.biopha.2022.113408 . (5

community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.